Contact – +1-276-477-5910
 Email – [email protected]

Home >>

Healthcare and Social Assistance

>>

Europe Active Pharmaceutical Ingredients API Market


Europe Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity

Report code: SDMRHE1298205 | Industry: Healthcare and Social Assistance | Published On: 44008


Europe active pharmaceutical ingredients (API) market reached $42.41 billion in 2019 and will grow by 7.6% annually over 2020-2026 owing to the rising need for medicine and pharmaceutical agents amid the COVID-19 pandemic.
Highlighted with 41 tables and 66 figures, this 133-page report “Europe Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.

Based on Synthesis, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
Synthetic API
• Branded Synthetic API
• Generic Synthetic API
Biotech API by Drug Type:
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Other Biotech APIs
Biotech API by Customer Base:
• Innovative Biologic API
• Generic Biosimilar API
Biotech API by Expression Technology:
• Mammalian Expression
• Microbial Expression
• Yeast Expression
• Insect Expression
• Other Expression Technologies
HPAPI
• Branded HPAPI
• Generic HPAPI

Based on Manufacturing Process, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
Captive Manufacturing
• Branded Captive API
• Generic Captive API
Merchant Manufacturing by Drug Type:
• Branded Merchant API
• Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
• Merchant Synthetic API
• Merchant Biotech API

Based on Therapeutic Application, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications

Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs

Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
For each aforementioned country, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe API market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
Bayer Healthcare
Bioniche Animal Health
Boehringer Ingelheim
Bristol-Myers Squibb
Ceva Animal Health, Inc.
Elanco Animal Health
Eli Lilly and Company
F. Hoffmann-La Roche
Glaxosmithkline PLC
Heska Co.
Lonza Group
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Ranbaxy Laboratories
Sanofi
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1  Introduction  7
1.1  Industry  Definition  and  Research  Scope  7
1.1.1  Industry  Definition  7
1.1.2  Research  Scope  8
1.2  Research  Methodology  11
1.2.1  Overview  of  Market  Research  Methodology  11
1.2.2  Market  Assumption  12
1.2.3  Secondary  Data  12
1.2.4  Primary  Data  12
1.2.5  Data  Filtration  and  Model  Design  14
1.2.6  Market  Size/Share  Estimation  15
1.2.7  Research  Limitations  16
1.3  Executive  Summary  17
2  Market  Overview  and  Dynamics  19
2.1  Market  Size  and  Forecast  19
2.2  Major  Growth  Drivers  20
2.3  Market  Restraints  and  Challenges  24
2.4  Emerging  Opportunities  and  Market  Trends  27
2.5  Porter’s  Fiver  Forces  Analysis  31
3  Segmentation  of  Europe  Market  by  Synthesis  35
3.1  Market  Overview  by  Synthesis  35
3.2  Synthetic  API  37
3.2.1  Branded  Synthetic  API  38
3.2.2  Generic  Synthetic  API  39
3.3  Biotech  API  40
3.3.1  Biotech  API  by  Drug  Type  41
3.3.1.1  Monoclonal  Antibodies  42
3.3.1.2  Recombinant  Proteins  43
3.3.1.3  Vaccines  44
3.3.1.4  Other  Biotech  APIs  45
3.3.2  Biotech  API  by  Customer  Base  46
3.3.2.1  Innovative  Biologic  API  47
3.3.2.2  Generic  Biosimilar  API  48
3.3.3  Biotech  API  by  Expression  Technology  49
3.3.3.1  Mammalian  Expression  50
3.3.3.2  Microbial  Expression  51
3.3.3.3  Yeast  Expression  52
3.3.3.4  Insect  Expression  53
3.3.3.5  Other  Expression  Technologies  54
3.4  HPAPI  55
3.4.1  Branded  HPAPI  56
3.4.2  Generic  HPAPI  57
4  Segmentation  of  Europe  Market  by  Manufacturing  Process  58
4.1  Market  Overview  by  Manufacturing  Process  58
4.2  Captive  Manufacturing  60
4.2.1  Branded  Captive  API  61
4.2.2  Generic  Captive  API  62
4.3  Merchant  Manufacturing  63
4.3.1  Merchant  Manufacturing  by  Drug  Type  64
4.3.1.1  Branded  Merchant  API  65
4.3.1.2  Generic  Merchant  API  66
4.3.2  Merchant  Manufacturing  by  Drug  Synthesis  67
4.3.2.1  Merchant  Synthetic  API  68
4.3.2.2  Merchant  Biotech  API  69
5  Segmentation  of  Europe  Market  by  Therapeutic  Application  70
5.1  Market  Overview  by  Therapeutic  Application  70
5.2  Infectious  Diseases  72
5.3  Oncology  73
5.4  Ophthalmology  74
5.5  Cardiovascular  Disorders  75
5.6  Central  Nervous  System  76
5.7  Pulmonary  Disorders  77
5.8  Orthopedics  78
5.9  Other  Applications  79
6  Segmentation  of  Europe  Market  by  Drug  Type  80
6.1  Market  Overview  by  Drug  Type  80
6.2  Branded  Prescription  Drugs  82
6.3  Generic  Prescription  Drugs  83
6.4  OTC  Drugs  84
7  European  Market  2019-2026  by  Country  85
7.1  Overview  of  European  Market  85
7.2  UK  88
7.3  France  90
7.4  Germany  92
7.5  Spain  94
7.6  Italy  96
7.7  Russia  98
7.8  Rest  of  European  Market  100
8  Competitive  Landscape  102
8.1  Overview  of  Key  Vendors  102
8.2  New  Product  Launch,  Partnership,  Investment,  and  M&A  105
8.3  Company  Profiles  106
AbbVie  Inc.  106
Astrazeneca  108
Aurobindo  Pharma  Ltd.  109
Bayer  Healthcare  110
Bioniche  Animal  Health  111
Boehringer  Ingelheim  112
Bristol-Myers  Squibb  113
Ceva  Animal  Health,  Inc.  114
Elanco  Animal  Health  115
Eli  Lilly  and  Company  116
F.  Hoffmann-La  Roche  117
Glaxosmithkline  PLC  118
Heska  Co.  119
Lonza  Group  120
Merck  &  Co.,  Inc.  121
Novartis  International  AG  122
Pfizer,  Inc.  123
Ranbaxy  Laboratories  124
Sanofi  125
Sun  Pharmaceutical  Industries  Ltd.  126
9  Investing  in  Europe  Market:  Risk  Assessment  and  Management  127
9.1  Risk  Evaluation  of  Europe  Market  127
9.2  Critical  Success  Factors  (CSFs)  130
Related  Reports  and  Products  133
Table 1. Snapshot of Europe Active Pharmaceutical Ingredients (API) Market, 2019-2026 18
Table 2. Main Product Trends and Market Opportunities in Europe Active Pharmaceutical Ingredients (API) Market 27
Table 3. Europe Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 35
Table 4. Europe Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2015-2026, $ bn 37
Table 5. Europe Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2015-2026, $ bn 41
Table 6. Europe Active Pharmaceutical Ingredients (API) Market: Biotech API by Customer Base, 2015-2026, $ bn 46
Table 7. Europe Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2015-2026, $ bn 49
Table 8. Europe Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2015-2026, $ bn 55
Table 9. Europe Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 58
Table 10. Europe Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2015-2026, $ bn 60
Table 11. Europe Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2015-2026, $ bn 64
Table 12. Europe Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2015-2026, $ bn 67
Table 13. Europe Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 70
Table 14. Europe Active Pharmaceutical Ingredients (API) Market by Drug Type, 2015-2026, $ bn 80
Table 15. Europe Active Pharmaceutical Ingredients (API) Market by Country, 2015-2026, $ bn 87
Table 16. UK Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 89
Table 17. UK Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 89
Table 18. UK Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 89
Table 19. France Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 91
Table 20. France Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 91
Table 21. France Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 91
Table 22. Germany Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 93
Table 23. Germany Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 93
Table 24. Germany Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 93
Table 25. Spain Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 95
Table 26. Spain Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 95
Table 27. Spain Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 95
Table 28. Italy Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 97
Table 29. Italy Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 97
Table 30. Italy Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 97
Table 31. Russia Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 99
Table 32. Russia Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 99
Table 33. Russia Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 99
Table 34. Active Pharmaceutical Ingredients (API) Market in Rest of Europe by Country, 2015-2026, $ bn 101
Table 35. AbbVie Inc.: Company Snapshot 106
Table 36. AbbVie Inc.: Business Segmentation 106
Table 37. AbbVie Inc.: Product Portfolio 107
Table 38. AbbVie Inc.: Revenue, 2016-2018, $ bn 107
Table 39. AbbVie Inc.: Recent Developments 107
Table 40. Risk Evaluation for Investing in Europe Market, 2019-2026 128
Table 41. Critical Success Factors and Key Takeaways 131
 Feel free to contact us

 
Choose License Type
Select User Type


Report code




x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT